Rise in prevalence of diseases such as axillary hyperhidrosis in developed countries, expanding product launches and product approvals, and surge in demand for improved healthcare services drive
Share this article
Share this article
WOBURN, Mass., March 9, 2021 /PRNewswire/ Today, Eirion Therapeutics, Inc., an aesthetic dermatology company headquartered in Woburn, Massachusetts, announced a deal with Shanghai Haohai Biological Technology Ltd. ( Haohai ) that will result in a $32 million Series A Preferred Stock investment into Eirion along with exclusive licenses that will be for all of Eirion s products for the territory of China in exchange for an upfront payment in the amount of $8 million. The deal is structured in segments over the next approximately 18 months. Haohai is a leading Chinese aesthetic medicine company headquartered in Shanghai and is publicly traded on the Hong Kong (6826.HK) and Shanghai (688366.SS) stock exchanges.